Articles with "ipilimumab nivolumab" as a keyword



Photo from wikipedia

Quality-of-life outcomes and risk prediction for patients randomized to Nivolumab/Ipilimumab vs Nivolumab on LungMAP-S1400I.

Sign Up to like & get
recommendations!
Published in 2023 at "Journal of the National Cancer Institute"

DOI: 10.1093/jnci/djad003

Abstract: BACKGROUND An important issue for patients with cancer treated with novel therapeutics is how they weigh the effects of treatment on survival and quality-of-life (QOL). We compared QOL in patients enrolled to SWOG-1400I, a substudy… read more here.

Keywords: ipilimumab nivolumab; risk; nivolumab ipilimumab; quality life ... See more keywords
Photo from wikipedia

Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma

Sign Up to like & get
recommendations!
Published in 2022 at "Melanoma Research"

DOI: 10.1097/cmr.0000000000000818

Abstract: Checkpoint immunotherapies (CPIs) have improved outcomes for metastatic melanoma patients, with objective response rates to combination ipilimumab and nivolumab of ~58%. Preclinical data suggest that histone deacetylase (HDAC) inhibition enhances antitumor immune activity and may… read more here.

Keywords: melanoma; inhibitor mocetinostat; mocetinostat; ipilimumab nivolumab ... See more keywords
Photo by des0519 from unsplash

795 A multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

Sign Up to like & get
recommendations!
Published in 2020 at "Journal for ImmunoTherapy of Cancer"

DOI: 10.1136/jitc-2020-sitc2020.0795

Abstract: Background Angiosarcoma is a rare cancer of endothelial cells that can be aggressive and carries a high mortality. A subset of angiosarcomas are characterized by high tumor mutational burden (TMB) and UV light exposure DNA… read more here.

Keywords: phase; trial; unresectable angiosarcoma; anti ... See more keywords
Photo from wikipedia

Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

Sign Up to like & get
recommendations!
Published in 2021 at "Journal for Immunotherapy of Cancer"

DOI: 10.1136/jitc-2021-002990

Abstract: Purpose Angiosarcoma is a rare aggressive endothelial cell cancer with high mortality. Isolated reports suggest immune checkpoint inhibition efficacy in angiosarcoma, but no prospective studies have been published. We report results for angiosarcoma treated with… read more here.

Keywords: trial; anti; multicenter phase; ipilimumab nivolumab ... See more keywords
Photo from wikipedia

FDG PET/CT Prognostic Markers in Patients with Advanced Melanoma Treated with Ipilimumab and Nivolumab.

Sign Up to like & get
recommendations!
Published in 2023 at "Radiology"

DOI: 10.1148/radiol.221180

Abstract: Background Despite improved response to combined ipilimumab and nivolumab (hereafter, IpiNivo) treatment for advanced melanoma, many patients exhibit primary or acquired resistance. This, combined with high risk of immune-related adverse events, makes identifying markers predictive… read more here.

Keywords: advanced melanoma; oncology; patients advanced; ipilimumab nivolumab ... See more keywords
Photo by hudsoncrafted from unsplash

Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine—Letter

Sign Up to like & get
recommendations!
Published in 2020 at "Clinical Cancer Research"

DOI: 10.1158/1078-0432.ccr-20-0443

Abstract: Patel and colleagues report the results of the basket trial (DART) studying the checkpoint inhibitors combination, ipilimumab plus nivolumab, in a cohort of patients with neuroendocrine neoplasms (NEN; ref. [1][1]). We commend the authors for… read more here.

Keywords: s1609 neuroendocrine; neuroendocrine letter; rare tumors; ipilimumab nivolumab ... See more keywords
Photo from wikipedia

A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)

Sign Up to like & get
recommendations!
Published in 2021 at "Clinical Cancer Research"

DOI: 10.1158/1078-0432.ccr-21-2182

Abstract: Purpose: Metaplastic breast cancer (MpBC) is a rare aggressive subtype that responds poorly to cytotoxics. Median survival is approximately 8 months for metastatic disease. We report results for advanced MpBC treated with ipilimumab + nivolumab,… read more here.

Keywords: anti; ipilimumab nivolumab; ipilimumab; breast cancer ... See more keywords
Photo from wikipedia

Combination therapy of ipilimumab and nivolumab induced thyroid storm in a patient with Hashimoto’s disease and diabetes mellitus: a case report

Sign Up to like & get
recommendations!
Published in 2018 at "Journal of Medical Case Reports"

DOI: 10.1186/s13256-018-1708-x

Abstract: BackgroundRecently, immune checkpoint inhibitors have widely been used for the management of advanced melanoma. However, high-grade immune-related adverse events can occur, particularly with combination immunotherapy. We report a case of a patient with melanoma who… read more here.

Keywords: hashimoto disease; thyroid storm; case; diabetes mellitus ... See more keywords
Photo from wikipedia

Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab

Sign Up to like & get
recommendations!
Published in 2018 at "Journal for Immunotherapy of Cancer"

DOI: 10.1186/s40425-018-0384-0

Abstract: BackgroundTreatment of metastatic melanoma patients with immune checkpoint inhibitors is an important standard of care. Side effects are due to immune activation, can affect virtually all organ systems, and are occasionally severe. Although hematologic toxicity… read more here.

Keywords: melanoma; patient treated; hemophagocytic lymphohistiocytosis; ipilimumab nivolumab ... See more keywords
Photo from wikipedia

Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy

Sign Up to like & get
recommendations!
Published in 2019 at "Journal for Immunotherapy of Cancer"

DOI: 10.1186/s40425-019-0655-4

Abstract: BackgroundHigh response rates of metastatic melanoma have been reported upon immune checkpoint inhibition by PD-1 blockade alone or in combination with CTLA-4 inhibitors. However, the majority of patients with a primary resistance to anti-PD-1 monotherapy… read more here.

Keywords: response; ipilimumab nivolumab; monotherapy; response combined ... See more keywords
Photo by finnnyc from unsplash

Neurologic Complications: Effects of Ipilimumab and Nivolumab Therapy in Patients With Metastatic Melanoma.

Sign Up to like & get
recommendations!
Published in 2019 at "Clinical journal of oncology nursing"

DOI: 10.1188/19.cjon.355-358

Abstract: Checkpoint inhibitors are a form of immunotherapy that have revolutionized treatment for malignant melanoma, resulting in longer survival and better disease control. Multiple autoimmune disorders can occur with the use of checkpoint inhibitors, including severe,… read more here.

Keywords: therapy patients; complications effects; effects ipilimumab; ipilimumab nivolumab ... See more keywords